"Several preclinical and translational data studies suggest potential causative effects on bone health. One study with GLP-1 ...

The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...

The once-daily oral GLP-1 RA orforglipron produces clinically and statistically significant weight loss and cardiometabolic ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

Lung cancer patients who take medications called GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes ...

DelveInsight's GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study.

GLP-1 receptor agonists vs other second-line therapies were not associated with an increased thyroid cancer risk among patients with type 2 diabetes.

Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer.

About The Study: This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of ...